March 10, 2022

Episode 8- Discussing Medical Affairs with Kelly Covello, PhD

Episode 8- Discussing Medical Affairs with Kelly Covello, PhD

Today The Biotech Project chats with Kelly Covello, PhD who has extensive experience in Medical Affairs.  She currently serves as the head of a medical affairs organization at a well respected biotech.  Kelly offers her perspective on her very own journe...

Apple Podcasts podcast player badge
iHeartRadio podcast player badge
Castro podcast player badge
RSS Feed podcast player badge
PlayerFM podcast player badge
Podcast Addict podcast player badge
Deezer podcast player badge
Spotify podcast player badge
Amazon Music podcast player badge
Apple Podcasts podcast player iconiHeartRadio podcast player iconCastro podcast player iconRSS Feed podcast player iconPlayerFM podcast player iconPodcast Addict podcast player iconDeezer podcast player iconSpotify podcast player iconAmazon Music podcast player icon

Today The Biotech Project chats with Kelly Covello, PhD who has extensive experience in Medical Affairs.  She currently serves as the head of a medical affairs organization at a well respected biotech.  Kelly offers her perspective on her very own journey from bench science and academia to the biopharma industry!

Kelly Covello Profile Photo

Kelly Covello, Ph.D. joined Mirati in April 2020 as Vice President, Head of Medical Affairs, bringing in more than 15 years of oncology pharmaceutical industry experience in diverse R&D roles spanning drug discovery, clinical development, and medical strategy.
Before joining Mirati, Dr. Covello held numerous roles of increasing responsibilities at Bristol-Myers Squibb, GlaxoSmithKline, and Boehringer Ingelheim. She was a Senior Early Development Team Lead responsible for the early development strategy of a portfolio of immuno-oncology assets. She also served as the Global Medical Lead for Lung Cancer and led the medical team to develop and execute the medical communication and non-registrational data generation strategy for Opdivo® and Yervoy®.
Dr. Covello’s experience also includes medical lead roles for Erbitux® and Gilotrif® and has led launch preparations for nivolumab across 5 indications, and the mage-a3 cancer vaccine for melanoma and NSCLC.
Dr. Covello received her B.S. in Biology from The College of New Jersey and earned her Ph.D., Cell and Molecular Biology from the University of Pennsylvania Medical School.